U.S. Government Achieves 2018 TB Research and Development Funding Target

U.S. Government Tuberculosis Research and Development Contributions

As the lead U.S. government agency for global tuberculosis (TB) control efforts, the United States Agency for International Development (USAID) is proud to announce that the U.S. has achieved its annual TB Research and Development (R&D) funding target for 2018. USAID, the National Institutes of Health (NIH), the Centers for Disease Control and Prevention (CDC), and the Department of Defense (DOD) have collectively mobilized approximately $491.5 million for TB R&D in fiscal year 2018, exceeding the $444.5 million annual gross domestic expenditure on research and development (GERD) target set at the 2018 United Nations General Assembly (UNGA) by the Treatment Action Group (TAG).

As the largest funder of TB research, accounting for more than 40 percent of the global target, the U.S. contribution is vital for ensuring new tools and approaches are available to tackle the TB epidemic. The U.S. is one of the few countries globally to reach this target.

At the 2018 UNGA, heads of state committed to accelerating efforts in ending TB by adopting an ambitious Political Declaration on TB. Among the many established targets, UN member states pledged “to mobilize sufficient and sustainable financing” for TB research “with the aim of increasing overall global investments to US$2 billion [per year], in order to close the US$1.3 billion gap in funding annually.” Governments were called upon to increase investments in TB R&D by contributing a fair share - 0.1 percent of their gross domestic expenditure on research and development.

R&D Funding Target Chart

Investing in R&D is an important step in ending TB in the U.S. and globally. Increased investments will lead to the identification of new rapid diagnostic tools for TB infection and diseases, including drug-resistant TB; innovative medicines and treatment regimens that are more effective, shorter, and well-tolerated, resulting in better treatment outcomes; novel vaccines or medicines to prevent the development of TB; and state-of-the-art approaches to further prevent TB transmission.

Fighting TB is a top priority for the United States government. In line with the U.S. Government TB strategy, there is a critical need to invest in developing and testing innovative methodologies to reach, prevent, diagnose, and cure TB in the U.S. and globally. By exceeding the TB R&D target, the U.S. Government, has taken an important step towards ending TB. USAID will continue to work closely with our sister agencies to engage other governments and advocates in an effort to help achieve their fair share investment in TB R&D.

Last updated: October 16, 2019

Share This Page